Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 28;25(1):440.
doi: 10.3390/ijms25010440.

Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction

Roxana Mihaela Chiorescu  1   2 , Roxana-Daiana Lazar  3 , Alexandru Ruda  3 , Andreea Paula Buda  3 , Stefan Chiorescu  4 , Mihaela Mocan  1   2 , Dan Blendea  3   5
Affiliations
Review

Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction

Roxana Mihaela Chiorescu et al. Int J Mol Sci. .

Abstract

Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.

Keywords: ejection fraction; heart failure; melatonina; microARN; serpina.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The main pathophysiological process involved in the development of HFpEF [10].
Figure 2
Figure 2
The main phenotypes and suitable treatment in patients with HFpEF [22].
Figure 3
Figure 3
The scores used to estimate the probability of underlying HFpEF [6,7].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368. - DOI - PubMed
    1. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., Olofsson B., Ostergren J., CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet. 2003;362:777–781. doi: 10.1016/S0140-6736(03)14285-7. - DOI - PubMed
    1. Nielsen O.W., Køber L., Torp-Pedersen C. Heart failure with preserved ejection fraction: Dangerous, elusive, and difficult. Eur. Heart J. 2008;29:285–287. doi: 10.1093/eurheartj/ehm597. - DOI - PubMed
    1. Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006;27:2338–2345. doi: 10.1093/eurheartj/ehl250. - DOI - PubMed
    1. Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., Clausell N., Desai A.S., Diaz R., Fleg J.L., et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014;370:1383–1392. doi: 10.1056/NEJMoa1313731. - DOI - PubMed